These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 12696997)

  • 21. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
    Greenamyre JT
    J Neural Transm Gen Sect; 1993; 91(2-3):255-69. PubMed ID: 8099800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U; Del Dotto P
    Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of glutamate in the pathophysiology of Parkinson's disease.
    Blandini F; Greenamyre JT; Nappi G
    Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
    [No Abstract]   [Full Text] [Related]  

  • 25. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
    Chase TN; Oh JD; Konitsiotis S
    J Neurol; 2000 Apr; 247 Suppl 2():II36-42. PubMed ID: 10991664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems.
    Brichta L; Greengard P; Flajolet M
    Trends Neurosci; 2013 Sep; 36(9):543-54. PubMed ID: 23876424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of striatal metabotropic glutamate receptors in Parkinson's disease.
    Ossowska K; Konieczny J; Wardas J; Gołembiowska K; Wolfarth S; Pilc A
    Amino Acids; 2002; 23(1-3):193-8. PubMed ID: 12373537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synaptic and cellular plasticity in Parkinson's disease.
    Chu HY
    Acta Pharmacol Sin; 2020 Apr; 41(4):447-452. PubMed ID: 32112041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glutamate antagonists and Parkinson's disease: a review of clinical data.
    Montastruc JL; Rascol O; Senard JM
    Neurosci Biobehav Rev; 1997 Jul; 21(4):477-80. PubMed ID: 9195605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.
    Simola N; Morelli M; Pinna A
    Curr Pharm Des; 2008; 14(15):1475-89. PubMed ID: 18537671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
    Mori A
    Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
    Amalric M; Lopez S; Goudet C; Fisone G; Battaglia G; Nicoletti F; Pin JP; Acher FC
    Neuropharmacology; 2013 Mar; 66():53-64. PubMed ID: 22664304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
    Litim N; Morissette M; Di Paolo T
    Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The delta-opioid receptor and Parkinson's disease.
    Huang JZ; Ren Y; Xu Y; Chen T; Xia TC; Li ZR; Zhao JN; Hua F; Sheng SY; Xia Y
    CNS Neurosci Ther; 2018 Dec; 24(12):1089-1099. PubMed ID: 30076686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nondopaminergic treatments for Parkinson's disease: current and future prospects.
    Freitas ME; Fox SH
    Neurodegener Dis Manag; 2016 Jun; 6(3):249-68. PubMed ID: 27230697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders.
    Rouse ST; Marino MJ; Bradley SR; Awad H; Wittmann M; Conn PJ
    Pharmacol Ther; 2000 Dec; 88(3):427-35. PubMed ID: 11337032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
    Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
    Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism.
    Oueslati A; Breysse N; Amalric M; Kerkerian-Le Goff L; Salin P
    Eur J Neurosci; 2005 Dec; 22(11):2765-74. PubMed ID: 16324110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.